LabCorp (LH) has made considerable strides during recent years. The investment attractiveness is particularly marked by the company's consistent expected earnings growth. Importantly, LH has held its quarterly dividend of $0.72, asserting solid financial stability. The corporation has been upgraded to a Buy rating by different institutions, such as UBS and Morgan Stanley, addressing the evolving portfolio and low leverage. Despite some Q1 earnings misses, LabCorp has raised its adjusted EPS guidance.
LabCorp's stock has climbed 25.6% this year, supported by increased revenue and revised price targets. Key acquisitions, such as select assets of BioReference Health's innovative oncology and clinical testing services businesses, are driving growth, while the stock's robust earnings are signs of conservative investment returns. The company recently launched Labcorp Whole Health Solutions, a holistic approach that is poised to make a difference in healthcare testing.
However, the announcement about LabCorp's CFO, Glenn Eisenberg, retiring causes some blips of uncertainty. LabCorp was also recently involved in a class-action lawsuit over alleged overcharges for tests.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 02 Aug 2007 07:00:00 GMT to Sat, 19 Jul 2025 12:36:05 GMT - Rating 7 - Innovation 3 - Information 8 - Rumor 5
